PharmacoEconomics

Keyphrases

Publications

volume 41, number 3, 2023

R Brett McQueen, Kelly E Anderson, Joseph F Levy, Josh J Carlson
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? PharmacoEconomics 41 (3) (2023)
Yuqiong Lu, Zhanjing Dai, Feng Chang, Li Wang, Jiafang He, Penghua Shi, Haitao Zhang, Yun Lu
Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment. PharmacoEconomics 41 (3) (2023)
Yuqiong Lu, Zhanjing Dai, Feng Chang, Li Wang, Jiafang He, Penghua Shi, Haitao Zhang, Yun Lu
Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment. PharmacoEconomics 41 (3) (2023)
R Brett McQueen, Kelly E Anderson, Joseph F Levy, Josh J Carlson
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Praveen Thokala, Tushar Srivastava, Robert Smith, Shijie Ren, Melanie D Whittington, Jamie Elvidge, Ruth Wong, Lesley Uttley
Living Health Technology Assessment: Issues, Challenges and Opportunities. PharmacoEconomics 41 (3) (2023)
Praveen Thokala, Tushar Srivastava, Robert Smith, Shijie Ren, Melanie D Whittington, Jamie Elvidge, Ruth Wong, Lesley Uttley
Living Health Technology Assessment: Issues, Challenges and Opportunities. PharmacoEconomics 41 (3) (2023)
R Brett McQueen, Kelly E Anderson, Joseph F Levy, Josh J Carlson
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? PharmacoEconomics 41 (3) (2023)
Yuqiong Lu, Zhanjing Dai, Feng Chang, Li Wang, Jiafang He, Penghua Shi, Haitao Zhang, Yun Lu
Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment. PharmacoEconomics 41 (3) (2023)
R Brett McQueen, Kelly E Anderson, Joseph F Levy, Josh J Carlson
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)
Praveen Thokala, Tushar Srivastava, Robert Smith, Shijie Ren, Melanie D Whittington, Jamie Elvidge, Ruth Wong, Lesley Uttley
Living Health Technology Assessment: Issues, Challenges and Opportunities. PharmacoEconomics 41 (3) (2023)
Yuqiong Lu, Zhanjing Dai, Feng Chang, Li Wang, Jiafang He, Penghua Shi, Haitao Zhang, Yun Lu
Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment. PharmacoEconomics 41 (3) (2023)
Antoinette D I van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M Govers, Frank Hoentjen, Manuela A Joore, Sabine E Grimm
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (3) (2023)

volume 41, number 4, 2023

Nannan Li, Charlotte Beaudart, Jane A Cauley, Steven W Ing, Nancy E Lane, Jean-Yves Reginster, Stuart Silverman, Andrea J Singer, Mickaël J C Hiligsmann
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics 41 (4) (2023)
Praveen Thokala, Pann Ei Hnynn Si, Monica Hernandez Alava, Alessandro Sasso, Thilo Schaufler, Marco Soro, James Fotheringham
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis. PharmacoEconomics 41 (4) (2023)
Tristan M Snowsill
Modelling the Cost-Effectiveness of Diagnostic Tests. PharmacoEconomics 41 (4) (2023)
John J Kim, Wasem Alsabbagh, William W L Wong
Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario. PharmacoEconomics 41 (4) (2023)
John J Kim, Wasem Alsabbagh, William W L Wong
Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario. PharmacoEconomics 41 (4) (2023)
Carina M Behr, Martijn J Oude Wolcherink, Maarten J IJzerman, Rozemarijn Vliegenthart, Hendrik Koffijberg
Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations. PharmacoEconomics 41 (4) (2023)
Mohamed N M T Al Khayat, Nigel Armstrong, Jeremy Howick, Susan O'Meara, Pawel Posadzki, Steve Ryder, Charlotte Ahmadu, Stefan R A Konings, Maarten J Postma, Steven Duffy, Robert F Wolff, Antoinette D I van Asselt
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (4) (2023)
Nannan Li, Charlotte Beaudart, Jane A Cauley, Steven W Ing, Nancy E Lane, Jean-Yves Reginster, Stuart Silverman, Andrea J Singer, Mickaël J C Hiligsmann
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics 41 (4) (2023)
Richard Norman, Brendan Mulhern, Emily Lancsar, Paula Lorgelly, Julie Ratcliffe, Deborah Street, Rosalie Viney
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia. PharmacoEconomics 41 (4) (2023)
Mohamed N M T Al Khayat, Nigel Armstrong, Jeremy Howick, Susan O'Meara, Pawel Posadzki, Steve Ryder, Charlotte Ahmadu, Stefan R A Konings, Maarten J Postma, Steven Duffy, Robert F Wolff, Antoinette D I van Asselt
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (4) (2023)
Mohamed N M T Al Khayat, Nigel Armstrong, Jeremy Howick, Susan O'Meara, Pawel Posadzki, Steve Ryder, Charlotte Ahmadu, Stefan R A Konings, Maarten J Postma, Steven Duffy, Robert F Wolff, Antoinette D I van Asselt
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (4) (2023)
Carina M Behr, Martijn J Oude Wolcherink, Maarten J IJzerman, Rozemarijn Vliegenthart, Hendrik Koffijberg
Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations. PharmacoEconomics 41 (4) (2023)
Richard Norman, Brendan Mulhern, Emily Lancsar, Paula Lorgelly, Julie Ratcliffe, Deborah Street, Rosalie Viney
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia. PharmacoEconomics 41 (4) (2023)
Mohamed N M T Al Khayat, Nigel Armstrong, Jeremy Howick, Susan O'Meara, Pawel Posadzki, Steve Ryder, Charlotte Ahmadu, Stefan R A Konings, Maarten J Postma, Steven Duffy, Robert F Wolff, Antoinette D I van Asselt
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (4) (2023)
Tristan M Snowsill
Modelling the Cost-Effectiveness of Diagnostic Tests. PharmacoEconomics 41 (4) (2023)
Carina M Behr, Martijn J Oude Wolcherink, Maarten J IJzerman, Rozemarijn Vliegenthart, Hendrik Koffijberg
Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations. PharmacoEconomics 41 (4) (2023)
Nannan Li, Charlotte Beaudart, Jane A Cauley, Steven W Ing, Nancy E Lane, Jean-Yves Reginster, Stuart Silverman, Andrea J Singer, Mickaël J C Hiligsmann
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics 41 (4) (2023)
Praveen Thokala, Pann Ei Hnynn Si, Monica Hernandez Alava, Alessandro Sasso, Thilo Schaufler, Marco Soro, James Fotheringham
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis. PharmacoEconomics 41 (4) (2023)
Carina M Behr, Martijn J Oude Wolcherink, Maarten J IJzerman, Rozemarijn Vliegenthart, Hendrik Koffijberg
Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations. PharmacoEconomics 41 (4) (2023)
Praveen Thokala, Pann Ei Hnynn Si, Monica Hernandez Alava, Alessandro Sasso, Thilo Schaufler, Marco Soro, James Fotheringham
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis. PharmacoEconomics 41 (4) (2023)
Nannan Li, Charlotte Beaudart, Jane A Cauley, Steven W Ing, Nancy E Lane, Jean-Yves Reginster, Stuart Silverman, Andrea J Singer, Mickaël J C Hiligsmann
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics 41 (4) (2023)
Tristan M Snowsill
Modelling the Cost-Effectiveness of Diagnostic Tests. PharmacoEconomics 41 (4) (2023)
Praveen Thokala, Pann Ei Hnynn Si, Monica Hernandez Alava, Alessandro Sasso, Thilo Schaufler, Marco Soro, James Fotheringham
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis. PharmacoEconomics 41 (4) (2023)
John J Kim, Wasem Alsabbagh, William W L Wong
Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario. PharmacoEconomics 41 (4) (2023)
Richard Norman, Brendan Mulhern, Emily Lancsar, Paula Lorgelly, Julie Ratcliffe, Deborah Street, Rosalie Viney
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia. PharmacoEconomics 41 (4) (2023)
Mengmeng Zhang, Yun Bao, Yi Yang, Melissa Kimber, Mitchell Levine, Feng Xie
Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study. PharmacoEconomics 41 (4) (2023)
Praveen Thokala, Pann Ei Hnynn Si, Monica Hernandez Alava, Alessandro Sasso, Thilo Schaufler, Marco Soro, James Fotheringham
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis. PharmacoEconomics 41 (4) (2023)
Richard Norman, Brendan Mulhern, Emily Lancsar, Paula Lorgelly, Julie Ratcliffe, Deborah Street, Rosalie Viney
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia. PharmacoEconomics 41 (4) (2023)
Mengmeng Zhang, Yun Bao, Yi Yang, Melissa Kimber, Mitchell Levine, Feng Xie
Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study. PharmacoEconomics 41 (4) (2023)
Richard Norman, Brendan Mulhern, Emily Lancsar, Paula Lorgelly, Julie Ratcliffe, Deborah Street, Rosalie Viney
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia. PharmacoEconomics 41 (4) (2023)
Nannan Li, Charlotte Beaudart, Jane A Cauley, Steven W Ing, Nancy E Lane, Jean-Yves Reginster, Stuart Silverman, Andrea J Singer, Mickaël J C Hiligsmann
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics 41 (4) (2023)
Mengmeng Zhang, Yun Bao, Yi Yang, Melissa Kimber, Mitchell Levine, Feng Xie
Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study. PharmacoEconomics 41 (4) (2023)
Mohamed N M T Al Khayat, Nigel Armstrong, Jeremy Howick, Susan O'Meara, Pawel Posadzki, Steve Ryder, Charlotte Ahmadu, Stefan R A Konings, Maarten J Postma, Steven Duffy, Robert F Wolff, Antoinette D I van Asselt
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 41 (4) (2023)
Carina M Behr, Martijn J Oude Wolcherink, Maarten J IJzerman, Rozemarijn Vliegenthart, Hendrik Koffijberg
Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations. PharmacoEconomics 41 (4) (2023)